Evidence map›Paper›PMID 37153499›Full record

ArticleTherapeutic advances in gastroenterology2023

Real-world outcomes associated with vonoprazan-based

Colin W Howden, Erin E Cook, Elyse Swallow, Karen Yang, Helen Guo, Corey Pelletier, Rinu Jacob, Kentaro Sugano

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Therapeutic advances in gastroenterology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Breaking barriers in the first-lineWorld journal of gastroenterology · 2025
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Colin W HowdenUniversity of Tennessee College of Medicine, Memphis, TN 38163, USA.
Erin E CookAnalysis Group, Inc., Boston, MA, USA.ORCID https://orcid.org/0000-0001-9737-9130
Elyse SwallowAnalysis Group, Inc., Boston, MA, USA.
Karen YangAnalysis Group, Inc., New York, NY, USA.
Helen GuoAnalysis Group, Inc., Los Angeles, CA, USA.
Corey PelletierPhathom Pharmaceuticals, Florham Park, NJ, USA.
Rinu JacobPhathom Pharmaceuticals, Florham Park, NJ, USA.
Kentaro SuganoJichi Medical University, Shimotsuke, Tochigi, Japan.
Analysis Group (United States) · USJichi Medical University · JPUniversity of Tennessee Health Science Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Japanese guidelines recommend triple therapy with vonoprazan or a proton pump inhibitor (PPI) in combination with antibiotics to treat Objectives: To compare patients treated with a vonoprazan-based or PPI-based regimen for Design: Retrospective matched cohort. Methods: We used data from the Japan Medical Data Center claims database (July 2014-January 2020) to identify adult patients with Results: Among 25,389 matched pairs, vonoprazan-treated patients had fewer all-cause and Conclusion: Patients with

Indexed as

eradication therapyhealthcare costshealthcare resource useHelicobacter pyloriJapanproton pump inhibitorvonoprazan

Identifiers

PMID37153499
PMCPMC10161293
OpenAlexW4372053870

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.